- High research and development costs and time for advanced medical devices.
- Need to develop products to a more mature stage to increase licensing or partnership opportunities.
- Challenges in establishing a fully localized R&D, manufacturing, and regulatory certification model for advanced medical devices in Taiwan.
- Well-developed upstream and downstream resources in developed countries compared to Taiwan.
Medeon Biodesign, Inc.
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, Medeon Biodesign, Inc. disclosed greenhouse gas emissions of 132.8K kg/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
132.8K kg/year
2023
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2023 | 132.8K kg/year |
| 2022 | 154.2K kg/year (2022) |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Reduced carbon emissions by 5% in 2023 compared to 2022 (132,838 kg vs 160,286 kg)
🎯 Climate & Sustainability Targets
🔜 Short-term
- Assist Terumo in obtaining Supplement PMA for the next-generation Cross-Seal product and launch it to market.
- Advance clinical trials for Urocross and Duett products.
- Expand CDMO services and improve production efficiency.
- Strengthen R&D capabilities and cultivate domestic talents.
🔭 Long-term
- Achieve long-term and stable positive cash flow through innovative medical device development and licensing, and CDMO business.
🌱 ESG Focus Areas
EnvironmentalSocialGovernance